Helix BioPharma (TSE:HBP) has released an update.
Helix BioPharma Corp., a clinical-stage biopharmaceutical company, showcased its innovative L-DOS47 platform at the World ADC San Diego, highlighting its potential in treating hard-to-treat cancers. The company is advancing towards a Phase II study for non-small cell lung cancer and exploring broader applications across various cancer types. Helix aims to expand its pipeline with new antibody-drug conjugates, emphasizing the transformative potential of its technology in oncology.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Paramount Global (NASDAQ:PARA) Gains From Yellowstone in Europe
- Ford (NYSE:F) Shares Slip After Huge New Fine
- Intel (NASDAQ:INTC) Notches Up Despite New Loss to AMD Processors
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
